Antimicrobials discovery against Staphylococcus aureus by high throughput screening of drug library.
10.3760/cma.j.cn112150-20230418-00302
- Author:
Peng Fei SHE
1
;
Yi Fan YANG
1
;
Lin Hui LI
1
;
Lin Ying ZHOU
2
;
Yong WU
2
Author Information
1. Department of Laboratory Medicine, the Third Xiangya Hospital, Central South University, Changsha 410013, China.
2. Department of Laboratory Medicine, the Affiliated Changsha Hospital of Xiangya School of Medicine (the First Hospital of Changsha), Central South University, Changsha 410005, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Staphylococcus aureus;
Anti-Bacterial Agents/pharmacology*;
High-Throughput Screening Assays;
Staphylococcal Infections;
Anti-Infective Agents/pharmacology*;
Microbial Sensitivity Tests;
Biofilms;
Antineoplastic Agents/pharmacology*;
Anti-Inflammatory Agents/pharmacology*;
Cardiovascular Agents/pharmacology*;
Metabolic Diseases
- From:
Chinese Journal of Preventive Medicine
2023;57(11):1855-1861
- CountryChina
- Language:Chinese
-
Abstract:
To develop antimicrobials against Staphylococcus aureus by high throughput screening of drug library. The type of this study is experimental research. The clinical isolates of S. aureus were collected from the sputum samples of respiratory inpatient department of the Third Xiangya Hospital of Central South University. The anti-planktonic cells growth inhibition activity of FDA-approved drugs library (including 1 573 molecules) was assessed by building a planktonic cells screening platform; The biofilm inhibitory effect of the FDA-approved drugs was detected by building a biofilm screening platform combined with crystal violet staining; Minimal inhibitory concentrations of the selected hits were determined by broth microdilution assay. Finally, the cytotoxicity of the selected hits was detected by CCK-8 assay. The results showed that 218 hits were exhibited effective growth inhibitory effects against S. aureus by setting the concentrations of the molecules in the FDA-approved library to 100 μmol/L. These selected molecules are mainly anti-infective drugs, accounting for 118 hits; Followed by anti-cancer drugs, anti-inflammatory/-immune drugs, neurological drugs, cardiovascular drugs, endocrine drugs, and metabolic disease drugs, which accounts for 40, 19, 12, 9, 8, and 3 hits; Other unclassified drugs accounts for 9 hits. The top 10 hits exhibiting anti-planktonic cells activity against S. aureus were mainly including antitumor drugs, followed by neurological drugs and unclassified drugs like vitamin K3 with the inhibition rate of 99.65%-100%. Similarly, the top 10 hits showing biofilm inhibitory effects against S. aureus were also mainly including antitumor drugs, followed by neurological drugs and anti-inflammatory/-immune drugs with the inhibition rate of 50.22%-92.95%. The minimal inhibitory concentration (MIC) of the 51 hits by second round screening was determined by micro-dilution assay, which mainly include the antitumor drugs, cardiovascular drugs, endocrine drugs, anti-inflammatory/-immune drugs, metabolic disease drugs, neurological drugs and other unclassified drugs accounted for 22, 5, 3, 9, 2, 5 and 5 hits, respectively, with the MICs of 1.56-50 μmol/L, 6.25-25 μmol/L, 6.25-25 μmol/L, 0.2-50 μmol/L, 25-50 μmol/L, 1.56-50 μmol/L and 0.1-12.5 μmol/L, respectively. In conclusion, the minimum inhibitory concentrations of small molecules screened through high-throughput assay are at the level of micromolar with strong drug development potential and high modifiability. The high effective anti-planktonic cells and anti-biofilm activity by these molecules are expected to provide new ideas for the development of new antimicrobials against S. aureus.
